登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002001 证券简称：新和成 公告编号：2025-032 浙江新和成股份有限公司 关于参与竞拍土地使用权的进展公告 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。具体内 容详见公司2025年5月20日在指定信息披露媒体及巨潮资讯网（http://www.cninfo.com.cn）上刊登的公 告。 二、土地竞拍情况进展 浙江新和成控股有限公司本次参与竞拍杭州市上城区四堡七堡单元JG1402-76地块土地使用权并已竞得 该地块土地使用权，与杭州市规划和自然资源局签订了《国有建设用地使用权出让合同》。现将具体情 况公告如下： 1、出让人：杭州市规划和自然资源局 2、受让人：浙江新和成控股有限公司 3、地块编号：杭政储出[2025]61 号 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、土地竞拍情况概述 浙江新和成股份有限公司（以下简称"公司"或"新和成"）第九届董事会第十三次会议审议通过《关于参 与竞拍土地使用权的议案》，同意公司以新设立的全资子公司浙江新和成 ...

证券代码：002001 证券简称：新和成 公告编号：2025-032 浙江新和成股份有限公司 关于参与竞拍土地使用权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、土地竞拍情况概述 浙江新和成股份有限公司（以下简称"公司"或"新和成"）第九届董事会 第十三次会议审议通过《关于参与竞拍土地使用权的议案》，同意公司以新设立 的全资子公司浙江新和成控股有限公司为竞拍主体，以自有资金或自筹资金参与 竞拍杭州市上城区四堡七堡单元 JG1402-76 地块土地使用权，竞拍价格不超过人 民币 115,000 万元，董事会在审议额度内授权公司管理层全权负责上述竞拍土地使 用权事项，授权浙江新和成控股有限公司法定代表人及其转授权人签署相关法律文 件。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。具体内容详见公司 2025 年 5 月 20 日在指定信息披露媒体及 巨潮资讯网（http://www.cninfo.com.cn）上刊登的公告。 二、土地竞拍情况进展 4、地块坐落：上城区（四堡七堡单元 JG1402-76 地块 ...

蜂鸟智造的中试产品间。记者 韦维 摄 氮化镓晶圆。天府绛溪实验室供图 建平台 ●第二批24家四川省中试研发平台于近日公布，全省中试平台总数已达35家 量子测控芯片。成都中微达信科技有限公司供图 量子计算测控系统产品。成都中微达信科技有限公司供图 ●全省有数百家各类中试平台，分布在企业、高校院所，还有部分独立市场化运行的中试平台 ●今年成都新增中试平台及概念验证中心44家，累计备案建成省级、市级中试平台和概念验证中心131家 看创新 ●电子科技大学与天府绛溪实验室联合发布了全球首个氮化镓量子光源芯片。这个芯片被称为量子互联网 的"心脏"，为量子信息传输提供了全新的材料和器件方案 ●中微达信推出国内首台量子计算测控系统ZW-QCS560系列，这款产品的快速反应能力处于国际前列，同样 为中国量子计算突破纠错阈值提供重要支撑 6月9日，午餐高峰期，成都某连锁餐厅的后厨一派新景象，取代厨师在灶台前掌勺的，是数台银白色炒菜机 器人。它们整齐排开，机械臂灵活舞动，料盒自动精准投送食材和佐料。翻炒、加热……短短3分钟，一道热气腾 腾的川味小炒便新鲜出锅。 "一人能管4台。"后厨总管对这些"新员工"赞不绝口，"相比传统厨房，效 ...

Group 1: Company Overview and Strategy - The company operates under two main technology platforms: "Chemical+" and "Biological+" [3] - The focus is on expanding the biological fermentation product line, including vitamins and amino acids [3][4] - The company aims to develop new products in the fields of nutrition, new materials, and flavoring agents [6] Group 2: Financial Performance - The flavor and fragrance segment achieved a revenue of 3.916 billion RMB in 2024, representing a year-on-year growth of 19.62% [4] - Cumulative dividend payments have reached 15.5 billion RMB, with a payout ratio of 30%-50% of annual net profit [8] - The company has implemented two cash dividends in 2025, totaling 2 RMB and 5 RMB per share [8] Group 3: Investment and Development - The company is investing in high-performance polymers and key intermediates, with applications in automotive and electronics [4] - A new liquid methionine project is in the trial production preparation stage [5] - The Tianjin nylon new materials project is awaiting approval for construction [5] Group 4: Market Expansion and Global Strategy - The company exports to over 100 countries, with more than 50% of sales coming from international markets [6] - Plans for overseas factories are being considered, with existing subsidiaries in regions like Hong Kong, Singapore, and Germany [6] Group 5: Innovation and Competitive Position - The company emphasizes innovation and collaboration to enhance product competitiveness [6] - It aims to achieve domestic production of key products like vitamins E and A, contributing to industry transformation [6] - The company is focused on deepening its product matrix and expanding its market presence [6]

关于回购公司股份进展的公告 证券代码：002001 证券简称：新和成 公告编号：2025-031 浙江新和成股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于2025年4月11日召开的第 九届董事会第十一次会议审议通过《关于回购公司股份方案的议案》，同意公司 使用自有资金或回购专项贷款以集中竞价交易的方式回购公司部分社会公众股 份，用于实施股权激励计划或员工持股计划。本次回购金额区间为30,000万元- 60,000万元，回购价格不超过人民币32元/股，具体回购股份的数量及占总股本的 比例以回购期满时实际回购数量为准。本次回购股份的实施期限为自公司董事会 审议通过回购股份方案之日起不超过12个月。 根据公司披露的《关于回购公司股份方案的公告》《回购股份报告书》（公告 编号：2025-010、2025-023）相关规定，若公司在回购期间内发生资本公积转增 股本、派发红利、送红股等除权除息事宜，自股价除权除息之日起，按照中国证 监会及深圳证券交易所的相关规定相应调整回购价格。公司 2025 年 5 月 21 ...

Production Capacity and Market Overview - The company has an annual production capacity of 60,000 tons for Vitamin E, achieving full production and sales in 2024 [3] - The solid methionine production capacity is 300,000 tons, with trial production preparations ongoing [3] - Taurine is widely used in health products and the market demand is steadily increasing [3] New Materials and Projects - The new materials segment includes PPS with a planned capacity of 30,000 tons, expected to achieve full production and sales in 2024 [3] - The Tianjin nylon new materials project has a total planned investment of 10 billion CNY, with ongoing routine maintenance expected to last 10-12 weeks [3][4] - The company aims to establish a complete nylon 66 integrated production system, with the first phase targeting an annual production of 100,000 tons of adiponitrile and hexamethylenediamine [4] Health and Biotechnology Developments - The health industry park focuses on human nutrition products, including Vitamin A, D3, E, and β-carotene, with growth achieved last year [4] - The company is expanding its biomanufacturing capabilities, with products including Vitamin C and various amino acids [4] Capital Expenditure and Share Buyback - Planned capital expenditures include projects in nylon new materials, flavor and fragrance, and amino acids, with a focus on capacity enhancement and cost reduction [5] - The company has initiated a share buyback program with a total amount between 300 million CNY and 600 million CNY, having repurchased 456,400 shares, accounting for 0.0148% of total share capital [5]

Group 1 - The Shanghai Composite Index opened high and fluctuated, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7798.06 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.26% in the past month, 2.71% in the past three months, and 4.75% year-to-date [1] - The CSI 300 Index samples are categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.23%), WuXi AppTec (16.45%), Pian Zai Huang (6.51%), Yunnan Baiyao (5.3%), Kelun Pharmaceutical (5.04%), East China Pharmaceutical (3.91%), New Horizon (3.59%), Changchun High-tech (3.57%), Shanghai Raist (3.34%), and Fosun Pharmaceutical (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.57% from the Shanghai Stock Exchange and 36.43% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: Chemical drugs (43.24%), Pharmaceutical and Biotechnology services (21.56%), Traditional Chinese medicine (18.83%), and Biological drugs (16.37%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to changes in industry classification and subsequent adjustments to the CSI 300 industry index samples [2]

Core Viewpoint - New Hope Liuhe (新和成) plans to expand its scale by participating in a land auction to support its long-term development needs, following a significant increase in its 2024 performance [2][4]. Group 1: Financial Performance - In 2024, New Hope Liuhe achieved a revenue of 21.609 billion yuan, representing a year-on-year increase of 20.91% [2]. - The net profit attributable to shareholders reached 5.868 billion yuan, marking a substantial year-on-year growth of 117.01% [2]. Group 2: Growth Drivers - The growth in performance is attributed to the release of new production capacity for methionine and the recovery of the downstream aquaculture industry, which led to price recovery for key products in the nutrition segment [3]. - The company has actively seized market opportunities, enhancing market share through coordinated production and sales efforts, resulting in increased sales volume and prices for its main products compared to the previous year [3]. Group 3: Strategic Initiatives - New Hope Liuhe is focusing on deepening its product offerings in the flavor and fragrance business, with plans for a new fragrance industrial park in Shandong covering approximately 1,000 acres [3]. - The company is also planning major projects including a new nylon materials project in Tianjin and new projects in flavor and fragrance, as well as PPS new materials [3]. - The auction for land use rights is aimed at establishing a new headquarters in Hangzhou, which will enhance the company's management and R&D capabilities, leveraging the region's favorable business environment and talent resources [4].

二、交易对方的基本情况 本次土地使用权出让方为杭州市规划和自然资源局，交易对方与公司不存在关 联关系，亦不属于失信被执行人。 证券代码：002001 证券简称：新和成 公告编号：2025-030 浙江新和成股份有限公司 关于参与竞拍土地使用权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"或"新和成"）于 2025 年 5 月 19 日召开的第九届董事会第十三次会议审议通过《关于参与竞拍土地使用权 的议案》，现就相关情况公告如下： 一、交易概述 为顺应公司业务规模的持续扩张，满足公司未来长远发展需要，公司以新设 立的全资子公司浙江新和成控股有限公司为竞拍主体，以自有资金或自筹资金参 与竞拍杭州市上城区四堡七堡单元 JG1402-76 地块土地使用权，竞拍价格不超过 人民币 115,000 万元，董事会在审议额度内授权公司管理层全权负责上述竞拍土地 使用权事项，授权浙江新和成控股有限公司法定代表人及其转授权人签署相关法律 文件。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 ...

证券代码：002001 证券简称：新和成 公告编号：2025-029 浙江新和成股份有限公司 第九届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十三次会议 于 2025 年 5 月 14 日以电子邮件方式发出会议通知，于 2025 年 5 月 19 日以现 场结合通讯的方式召开，应出席董事 11 名，实际出席董事 11 名，符合《公司法》 和《公司章程》的规定。会议经表决形成决议如下： 会议以 11 票同意，0 票反对，0 票弃权审议通过《关于参与竞拍土地使用权 的议案》；本议案在提交董事会审议前已经公司董事会战略委员会审议通过。 董事会同意公司以新设立的全资子公司浙江新和成控股有限公司为竞拍主 体，以自有资金或自筹资金参与竞拍杭州市上城区四堡七堡单元 JG1402-76 地块 土地使用权。 《关于参与竞拍土地使用权的公告》详见公司同日在指定信息披露媒体及巨 潮资讯网（http://www.cninfo.com.cn）刊登的公告。 特此公告。 浙江新和成股份有限公司董事会 ...